- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
Systemic immunoglobulin light-chain (AL) amyloidosis is a disease characterized by the deposition of light chain amyloid fibrils produced by clonal CD38+ plasma cells. In a new phase 3
randomized controlled trial, a significantly higher proportion of patients with newly diagnosed AL amyloidosis who received the anti-CD38 antibody, daratumumab, on top of control therapy
achieved the primary end point of a haematologic complete response compared with those who received control treatment only (53.3% versus 18.1%). Patients in the daratumumab group were also
more likely than those in the control group to have survival free from major organ deterioration or haematologic progression.
Anyone you share the following link with will be able to read this content:
